The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes

Table 1

The summary of LEAD program. FPG—fasting plasma glucose, HbA1c—glycated hemoglobin, SBP—systolic blood pressure.

	𝑛	Mean change in HbA1c from initial values (%)	Mean change in FPG from initial values (mmol/L)	Mean change in body weight from initial values (kg)	Mean change of SBP from initial values (mmHg)
LEAD-3 (1573): Liraglutide in monotherapy versus glimepiride
Liraglutide 1,2 mg	251	−0,8	−0,84	−2,05	−2,12
Liraglutide 1,8 mg	247	−1,1	−1,42	−2,45	−3,64
Glimepirde 8 mg	248	0,5	−0,29	+1,12	−0,69
LEAD-2 (1572): Liraglutide with metformin versus glimepiride
Liraglutide 1,2 mg	241	−1	−1,64	−2,6	−2,8
Liraglutide 1,8 mg	242	−1	−1,69	−2,8	−2,3
Glimepiride 4 mg	244	−1	−1,31	+1	+0,4
LEAD-1 (1436): Liraglutide with glimeperide versus rosiglitazone
Liraglutide 1,2 mg	228	−1,1	−1,57	+0,3	−2,6
Liraglutide 1,8 mg	234	−1,1	−1,59	−0,2	−2,8
Rosiglitazone 4 mg	232	−0,4	−0,88	+2,1	−0,9
Placebo	114	+0,2	+1,01	−0,1	−2,3
LEAD-4 (1574): Liraglutide with metformin and rosiglitazone versus placebo
Liraglutide 1,2 mg	178	−1,5	−2,2	−1	−6,7
Liraglutide 1,8 mg	178	−1,5	−2,4	−2	−5,6
Placebo	177	−0,5	−0,43	+0,6	−1,1
LEAD-6 (1797): Liraglutide with metformin and/or glimepiride versus exenatide
Liraglutide 1,8 mg	233	−1,1	−1,61	−3,24	−2,51
Exenatide 10 𝜇g	231	−0,8	−0,6	−2,87	−2